comparemela.com

Latest Breaking News On - Editas medicine inc - Page 11 : comparemela.com

Editas Medicine, Inc (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript

Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.

United statesGreg harrisonLinda burklyGilmore oneillBaisong meiCaren deardorfBrian chengErick luceraJoon leeCristi barnettSamantha semenkowCorporate communicationsEditas medicine incVertex pharmaceuticalsEditas medicineCall transcript february

CEO Dumps 20 Million Ginkgo Bioworks Shares

Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?

United statesBarry cantonJason kellyReshma shettyAustin cheEditas medicine incAmerican tower corpDraftkings incGinkgo bioworks holdings incGinkgo bioworks holdingsKnow about ginkgoAmerican towerGeneral electricGinkgo bioworksEditas medicineNew seats available

Editas Medicine, Inc (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript

Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.

United statesCristi barnettSamantha semenkowBrian chengErick luceraJoon leeBaisong meiGilmore oneillCaren deardorfGreg harrisonLinda burklyEditas medicine incCorporate communicationsVertex pharmaceuticalsMost valuable electric car companiesEditas medicine

Editas Medicine Up 28% On Narrower Q4 Loss

Shares of Editas Medicine, Inc. (EDIT) are climbing more than 28 percent on Wednesday morning trade after the company reported narrower net loss for the fourth quarter, compared to the prior year.

Editas medicine incEditas medicine

Editas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing Trials

Key Financial Highlights and Business Updates for Q4 and Full Year 2023

Cristi barnettEditas medicine incVertex pharmaceuticalsEditas medicineGene editingSevere sickle cell diseaseTransfusion dependent beta thalassemiaBiologics license application

vimarsana © 2020. All Rights Reserved.